WO2010151004A3 - 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 - Google Patents

하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 Download PDF

Info

Publication number
WO2010151004A3
WO2010151004A3 PCT/KR2010/003937 KR2010003937W WO2010151004A3 WO 2010151004 A3 WO2010151004 A3 WO 2010151004A3 KR 2010003937 W KR2010003937 W KR 2010003937W WO 2010151004 A3 WO2010151004 A3 WO 2010151004A3
Authority
WO
WIPO (PCT)
Prior art keywords
local administration
injectable composition
composition containing
treating hemorrhoids
hydroxychloroquine
Prior art date
Application number
PCT/KR2010/003937
Other languages
English (en)
French (fr)
Other versions
WO2010151004A9 (ko
WO2010151004A2 (ko
Inventor
여오영
Original Assignee
Yeo Oh-Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeo Oh-Young filed Critical Yeo Oh-Young
Priority to EP10792286.6A priority Critical patent/EP2468257A4/en
Priority to JP2012517374A priority patent/JP5342695B2/ja
Priority to BRPI1010072A priority patent/BRPI1010072A2/pt
Priority to US13/379,626 priority patent/US8871228B2/en
Priority to RU2012100621/15A priority patent/RU2530605C2/ru
Priority to AU2010263478A priority patent/AU2010263478A1/en
Priority to CN2010800280712A priority patent/CN102481252A/zh
Publication of WO2010151004A2 publication Critical patent/WO2010151004A2/ko
Publication of WO2010151004A3 publication Critical patent/WO2010151004A3/ko
Publication of WO2010151004A9 publication Critical patent/WO2010151004A9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 하이드록시클로로퀸(hydroxychloroquine)을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물에 관한 것이다. 구체적으로는 하이드록시클로로퀸(hydroxychloroquine)을 주사용 생리식염액에 용해하고 국소마취제와 항산화제를 함유하는 국소투여용 주사제 조성물에 관한 것이다.
PCT/KR2010/003937 2009-06-23 2010-06-18 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 WO2010151004A2 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP10792286.6A EP2468257A4 (en) 2009-06-23 2010-06-18 INJECTABLE COMPOSITION CONTAINING HYDROXYCHLOROQUINE FOR LOCAL ADMINISTRATION FOR THE TREATMENT OF HEMORRHOIDS
JP2012517374A JP5342695B2 (ja) 2009-06-23 2010-06-18 ヒドロキシクロロキンを含有する痔核治療のための局所投与用注射剤組成物
BRPI1010072A BRPI1010072A2 (pt) 2009-06-23 2010-06-18 composição injetavel contendo hidroxicloroquina para administração local para o tratamento de hemorróida
US13/379,626 US8871228B2 (en) 2009-06-23 2010-06-18 Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids
RU2012100621/15A RU2530605C2 (ru) 2009-06-23 2010-06-18 Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении геморроя
AU2010263478A AU2010263478A1 (en) 2009-06-23 2010-06-18 Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids
CN2010800280712A CN102481252A (zh) 2009-06-23 2010-06-18 含有羟基氯喹的用于痔核治疗的局部投药用注射剂组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0055860 2009-06-23
KR1020090055860A KR101067443B1 (ko) 2009-06-23 2009-06-23 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물

Publications (3)

Publication Number Publication Date
WO2010151004A2 WO2010151004A2 (ko) 2010-12-29
WO2010151004A3 true WO2010151004A3 (ko) 2011-05-19
WO2010151004A9 WO2010151004A9 (ko) 2011-07-07

Family

ID=43387010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003937 WO2010151004A2 (ko) 2009-06-23 2010-06-18 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물

Country Status (9)

Country Link
US (1) US8871228B2 (ko)
EP (1) EP2468257A4 (ko)
JP (1) JP5342695B2 (ko)
KR (1) KR101067443B1 (ko)
CN (1) CN102481252A (ko)
AU (1) AU2010263478A1 (ko)
BR (1) BRPI1010072A2 (ko)
RU (1) RU2530605C2 (ko)
WO (1) WO2010151004A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101253565B1 (ko) 2009-09-22 2013-04-11 삼성전자주식회사 디스플레이 장치
KR101698003B1 (ko) 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
RU2657511C2 (ru) * 2016-08-15 2018-06-14 Общество с ограниченной ответственностью "ИБМХ-ЭкоБиоТех" (ООО "ИБМХ-ЭкоБиоТех") Способ получения фармакопейного экстракта
CN115317483A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 氯喹及其衍生物在制备PGCCs抑制剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020040767A (ko) * 1999-08-03 2002-05-30 아베데 파르마 게엠베하 운트 콤파니 카게 개와 고양이에서 퇴행성 관절 질환으로 인한 통증을경감시키기 위한 플루피르틴의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
DE19634313A1 (de) * 1996-08-24 1998-02-26 Behringwerke Ag Methode zur Stabilisierung von Plättchen
RU2174396C2 (ru) * 1997-03-20 2001-10-10 Панацея Биотек Лтд. Фармацевтическая композиция для подавления и лечения аноректальных и ободочно-кишечных болезней
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
WO2002009714A1 (en) 2000-07-31 2002-02-07 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
KR100390332B1 (ko) * 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
EP1450803A4 (en) * 2001-11-09 2008-09-03 Lauren Charous NEW USES FOR ANTIMALARIAL THERAPEUTIC AGENTS
AU2003287100A1 (en) * 2002-11-08 2004-06-03 Kin-Ping Wong Compositions containing an active fraction isolated from lycium barbarum and methods of using the same
AU2003287099A1 (en) * 2002-11-08 2004-06-03 Kin-Ping Wong Extract of trapa natans and methods of using the same
JP4791682B2 (ja) 2003-02-21 2011-10-12 帝國製薬株式会社 痔疾患用治療剤
JP4239036B2 (ja) * 2005-02-21 2009-03-18 ラウト，ラジーブ 改良薬剤組成物
US20080221150A1 (en) * 2005-08-13 2008-09-11 Shacka John J Prevention of Neurodegeneration by Macrolide Antibiotics
KR20080105857A (ko) 2007-06-01 2008-12-04 주식회사 비앤씨엘 치질환 및 기타 항문 직장 질환 치료 활성을 가지는조성물과 이의 제조 방법 및 이를 이용한 치질환 치료제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020040767A (ko) * 1999-08-03 2002-05-30 아베데 파르마 게엠베하 운트 콤파니 카게 개와 고양이에서 퇴행성 관절 질환으로 인한 통증을경감시키기 위한 플루피르틴의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLARK, P. ET AL.: "Hydroxychloroquine Compared with Placebo in Rheumatoid Arthritis.", ANNALS OF INTERNAL MEDICINE., vol. 119, no. 11, 1993, pages 1067 - 1071, XP008148632 *
O'DELL, J. R. ET AL.: "Treatment of Rhenumatoid Arthritis with Methotrexate alone, Sulfasalzine and Hydroxychloroquine, or a Combination of All Three Medications.", THE NEW ENGLAND JOURNAL OF MEDICINE., vol. 334, no. 20, 1996, pages 1287 - 1291, XP008141323 *
RAOULT, D. ET AL.: "Treatment of Q Fever Endocarditis.", ARCH INTERN MED., vol. 159, 1999, pages 167 - 173, XP008148641 *

Also Published As

Publication number Publication date
KR20100137692A (ko) 2010-12-31
BRPI1010072A2 (pt) 2016-03-15
US8871228B2 (en) 2014-10-28
CN102481252A (zh) 2012-05-30
WO2010151004A9 (ko) 2011-07-07
US20120108633A1 (en) 2012-05-03
RU2012100621A (ru) 2013-07-27
EP2468257A2 (en) 2012-06-27
JP5342695B2 (ja) 2013-11-13
RU2530605C2 (ru) 2014-10-10
AU2010263478A1 (en) 2012-02-02
EP2468257A4 (en) 2014-02-19
JP2012530777A (ja) 2012-12-06
WO2010151004A2 (ko) 2010-12-29
KR101067443B1 (ko) 2011-09-27

Similar Documents

Publication Publication Date Title
EA201300898A1 (ru) Композиция для окислительного фотоактивируемого омоложения кожи, содержащая гиалуроновую кислоту, глюкозамин или аллантоин
GB201216932D0 (en) Use of cannabinoids in combinationwith an anti-psychotic medicament
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
MX346003B (es) Composiciones orales antibacterianas.
WO2011069010A3 (en) Amantadine compositions and methods of use
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
WO2010151004A3 (ko) 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
WO2011039629A3 (es) Fracción bioactiva de petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer
MX2016006927A (es) Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevencion de la dermatitis atopica.
MX2010011401A (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica.
MX337145B (es) Composiciones farmaceuticas.
WO2008139313A8 (es) Solución anestésica transparente de propofolol, con baja irritación venosa
UA92423C2 (ru) Антибактериальная композиция
WO2011069149A3 (en) Cathepsin s inhibitors
UA29207U (ru) Способ лечения невынашеваемости беременности
EA201290285A1 (ru) Многослойная фармацевтическая композиция, диспергируемая в воде, содержащая комбинацию противомалярийных средств

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080028071.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792286

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13379626

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012517374

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010792286

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 40/MUMNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010263478

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2012100621

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2010263478

Country of ref document: AU

Date of ref document: 20100618

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1010072

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1010072

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111222